Figure 4.
nMOFs for PDT-driven Cancer Immunotherapy. Mechanism of the nMOFs to induce a PDT-mediated immune response, and combination with (A) IDO inhibitor or (B) αPD-1 in cancer immunotherapy. (C) CLSM imaging of tumor cells incubated with DCFH-DA and TBP-nMOFs in (b) under dark, (c) 5% O2 or (d) 21% O2 under light irradiation. (D) Growth curves of 4T1 tumor-bearing mice after receiving different formulations. (E) Frequency of CD8+ cells in tumors treated with different formulations. Reproduced with permission 75, 76. Copyright 2016 and 2018, American Chemical Society.